"What I really want to find out about is the status of the IND. The longer that drags on, the more worried I am that there are problems of some kind with the compound, either pertaining to stability or toxicology. If they can't get a low-impact approved for chronic use, corx is toast."
I agree Enemem. It is of utmost importance for any credibility going forward for this not to fall into the same category as all of their other predictions. Here's hoping........
Cordially,
RBlatch
Market Data 
Markets 
AI
